Matthew Richmond Laudel, PT, DPT | |
1750 Founders Pkwy Ste 126, Alpharetta, GA 30009-7600 | |
(770) 442-0727 | |
(770) 343-9607 |
Full Name | Matthew Richmond Laudel |
---|---|
Gender | Male |
Speciality | Physical Therapist |
Location | 1750 Founders Pkwy Ste 126, Alpharetta, Georgia |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1053890459 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2081S0010X | Physical Medicine & Rehabilitation - Sports Medicine | PT13513 (Georgia) | Secondary |
225100000X | Physical Therapist | PT13513 (Georgia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Matthew Richmond Laudel, PT, DPT 1750 Founders Pkwy Ste 126, Alpharetta, GA 30009-7600 Ph: (770) 442-0727 | Matthew Richmond Laudel, PT, DPT 1750 Founders Pkwy Ste 126, Alpharetta, GA 30009-7600 Ph: (770) 442-0727 |
News Archive
New research suggests that the complex meshwork of proteins and potentially other biomolecules that provides structural and biochemical support to surrounding cells in the brain may play an important role in Alzheimer's disease.
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
While interviewing for postgraduate residency positions soon after giving birth to her third child, Dr. Sharona Ross recalls, she was very hesitant to bring up her infant and two small children at home. She thought it would hurt her chances for a career in surgery.
The human opportunistic pathogen, Pseudomonas aeruginosa, has broken the immune system's code, report researchers from the University of Chicago, enabling the bacteria to recognize when its host is most vulnerable and to launch an attack before the weakened host can muster its defenses.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has launched a Phase 1 clinical trial to test an investigational vaccine intended to provide broad protection against a range of mosquito-transmitted diseases, such as Zika, malaria, West Nile fever and dengue fever, and to hinder the ability of mosquitoes to transmit such infections.
› Verified 9 days ago